Trial Profile

A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD3-anti-HER2-activated T-cells (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
Indications Advanced breast cancer; Early breast cancer
Focus Therapeutic Use

05 Apr 2023 Status changed from active, no longer recruiting to discontinued.
13 Apr 2018 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.
05 Dec 2016 Status changed from suspended to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com